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Abstract 
Background: Hepatitis C virus (HCV) is one of the main causes of chronic liver disease 
worldwide. Prevalence of HCV in homeless populations ranges from 3.9% to 36.2%. The 
HepCheck study sought to investigate and establish the characterisation of HCV burden 
among  individuals who attended an intensified screening programme for HCV in homeless 
services in Dublin, Ireland. 
Methods: The HepCheck study was conducted as part of a larger European wide initiative 
called HepCare Europe. The study consisted of three phases; 1) all subjects completed a short 
survey and were offered a rapid oral HCV test; 2) a convenience sample of HCV positive 
participants from phase 1 were selected to complete a survey on health and social risk factors 
and 3) subjects were tracked along the referral pathway to identify whether they were referred 
to a specialist clinic, attended the specialist clinic, were assessed for cirrhosis by transient 
elastography (Fibroscan) and were treated for HCV. 
Results: 597 individuals were offered HCV screening, 73% were male and 63% reported 
having had a previous HCV screening. We screened 538 (90%) of those offered screening, 
with 37% testing positive. Among those who tested positive, 112 (56%) were ‘new positives’ 
and 44% were ‘known positives’. Undiagnosed HCV was prevalent in 19% of the study 
sample. Active past 30-day drug use was common, along with attendance for drug treatment. 
Unstable accommodation was the most common barrier to attending specialist appointments 
and accessing treatment.  Depression and anxiety, dental problems and respiratory conditions 
were common reported health problems. 46 subjects were referred to specialised services and 
two subjects completed HCV treatment.  
Conclusions: This study demonstrates that the current hospital-based model of care is 
inadequate in addressing the specific needs of a homeless population and emphasises the 
need for a community-based treatment approach. Findings are intended to inform HepCare 
Europe in their development of a community-based model of care in order to engage with 
homeless individuals with multiple co-morbidities including substance abuse, who are 
affected by or infected with HCV. 
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Introduction 
Hepatitis C virus (HCV) is one of the main causes of chronic liver disease worldwide (1). 
The long-term impact of HCV infection is highly variable, from minimal changes to 
extensive ﬁbrosis and cirrhosis with or without hepatocellular carcinoma (HCC) (2,3). Acute 
infection is asymptomatic in 60-70% of cases, meaning that many do not become aware that 
they are HCV positive until decades after initial infection, after progression of the disease and 
emergence of sequelae (4). Effective diagnosis and treatment is heavily reliant on screening 
of at-risk individuals (5). The number of chronically infected persons worldwide is estimated 
to be approximately 71 million (6). The implementation of extended criteria for screening of 
HCV is currently the subject of major debate among different stakeholders (7).  
A 2012 systematic review and meta-analysis of HCV in homeless populations found 
prevalence ranging from 3.9% to 36.2% (8). Homelessness is associated with an increased 
prevalence of risk factors for HCV such as injecting drug use (IDU) (9,10). The link between 
homelessness and poor health is well established (11–13). Homeless individuals generally 
delay going to a health service and so when they eventually do present, it is generally late on 
in their condition and can often have become so severe that they require hospitalisation. 
Preventing the transmission of blood borne viruses (BBV) such as HCV is therefore a key 
responsibility of community health services and their partners in homeless services (8,14–
17). High levels of alcohol use, as well as diabetes and metabolic syndrome suggest probable 
higher rates of fatty liver disease among this population (9,18).  
In Ireland, where our study took place, it is estimated that 20,000-50,000 people are 
chronically infected with HCV (19). Of the six HCV genotypes, Genotype 1 and 3 are most 
common in Ireland. National data on HCV infection in Ireland amongst drug users is 
restricted to certain treatment sites and prisons (20). Keegan et al. (2017) in their study 
reported that prevalence of HCV infection among drug users was 63.6% with no significant 
gender difference and with prevalence lower in younger adults. General prevalence estimates 
within the drug user populations range from 54% (21) to 84% (22). In terms of homeless 
adults in Dublin, in 2005 the rate of HCV infection was estimated to be 36% (23). A 2015 
study of people who are homeless/at risk of homelessness receiving free primary healthcare 
in Dublin reported a HCV prevalence of 23% (16). Information on the extent of chronic liver 
disease amongst homeless individuals in Ireland is however limited. There is substandard 
uptake in HCV assessment and treatment among people who inject drugs (PWID) in Ireland 
(24).   
The Irish Health Service Executive (HSE) funded Safetynet Primary Care service is a 
network of general practitioners and nurses providing primary care to homeless and other 
marginalised groups. This multifaceted service includes the offering of treatment in their own 
environment to homeless people who are addicted to heroin, thus removing many of the 
barriers that result in their exclusion from treatment. It provides a novel alternative to the 
centralised clinic approach, which was the only option for homeless people prior to the 
project’s establishment. In Dublin, homeless heroin dependant patients can access methadone 
maintenance treatment through Safetynet services (as well as HSE addiction centres). Our 
study sought to evaluate an intensified screening programme for HCV in homeless 
individuals attending Primary Care services in Dublin, Ireland, and in doing so investigate 
and establish the characterisation of HCV burden among this cohort.  
 Methods 
HepCheck Dublin was undertaken as part of a larger European wide initiative called HepCare 
Europe. HepCare Europe is an EU-supported service innovation project and feasibility study 
at four European sites (Dublin, London, Seville and Bucharest) to develop, implement and 
evaluate interventions to enhance identification and treatment of HCV among vulnerable 
populations (25). The project focuses on providing an ‘integrated care’ model for HCV 
treatment based on collaboration between primary and specialist care practitioners to allow 
for more efficient use of limited specialist resources. The HepCheck Dublin project looks 
specifically at screening individuals using rapid HCV testing and tracking results and 
pathways to care outcomes. 
 
This study used a cohort design. The target population were homeless individuals accessing 
the Safetynet Primary Care services in Dublin. Individuals using homeless services and 
hostels (Merchant’s Quay Ireland (MQI), Capuchin Day Centre, Ana Liffey Drug Project 
(ALDP), Salvation Army, De Paul Ireland, Crosscare, the Dublin Simon Community and the 
Safetynet mobile health unit) were informed of screening for HCV in Safetynet clinics and 
encouraged to attend. Individuals who reported that they had already been diagnosed as 
having HCV were advised to attend a safetynet clinic for assessment and referral for 
treatment if appropriate. Screening took place in 11 Safetynet affiliated GP practices, as well 
as Safetynet in-reach locations such as coffee shops, needle exchanges, hostels, drop in 
centres, and the Safetynet mobile health unit. 
Inclusion criteria were as follows: 1) attended Safetynet services during the study period, 2) 
age >18, and 3) ability to provide informed consent. Exclusion criterion was defined as 
inability to provide informed consent. Subjects were given an information sheet on the study 
and provided written consent. Subjects were recruited over a 19-month period, from 
December 2014 to July 2016. As conventional probability methods, such as simple or 
stratified random sampling, are often not appropriate for populations of injecting drug users 
(26), targeted sampling, a non-probability sampling framework, was used to identify subjects 
on whom data was collected (27). Subjects received no financial incentive for participation in 
the study. 
The HCV process audit consisted of 3 phases;  
In Phase One, during an intensified community HCV screening program, all subjects 
attending services were invited to complete a short questionnaire and offered blood test or 
rapid oral HCV test, and if found positive, participation in Phase 3 of the study. OraQuick® 
oral swab was used as a point of care test for HCV antibodies. Each subject completed a 
questionnaire which was administered by a research assistant who accompanied the nurse. 
This questionnaire collected information on the number of individuals offered HCV 
screening, number of individuals screened, proportion of individuals offered screening who 
already had been diagnosed as having HCV, the treatment status of individuals already 
diagnosed with HCV (cured/treated but not cured/awaiting treatment/defaulted from follow-
up/never referred to specialist treatment), the proportion of individuals with positive HCV 
antibody (HCV Ab+) on screening, and the number of HCV Ab+ individuals (either new or 
previously diagnosed) attending for HCV assessment. Demographic information was also 
collected regarding age, gender, ethnicity, injecting drug use, alcohol use, accommodation 
status and keyworker involvement. The keyworker is a member of a multidisciplinary team 
who is tasked with coordinating service user’s support plan.  
As the treatment pathway in Ireland is restricted to hospital based care HCV+ patients were 
referred to Mater Misericordiae University Hospital for specialist care. 
In Phase Two, a convenience sample of participants who in Phase 1 reported previously 
testing HCV positive (i.e. known positive) were administered an in-depth questionnaire by a 
researcher during screening clinics. The questionnaire comprised 79 closed and open-ended 
questions. Questions asked explored health and social risk factors, including: homelessness 
experience, health status, health service usage, co-morbidities, when diagnosis was made and 
the steps that were taken post positive HCV Ab test. The purpose of this questionnaire was to 
identify barriers to follow-up. 
Lastly, in Phase 3, subjects testing positive in Phase 1 were tracked along the referral 
pathway to identify whether they were referred to a specialist clinic, attended the specialist 
clinic, were assessed for cirrhosis by Fibroscan and were treated for HCV. Where possible, a 
key worker was involved in linking the subject to specialist care. Subjects were given a 
minimum of 3 appointments for a specialist clinic. Subjects were eligible for treatment with 
direct-acting antivirals if they had a Fibroscan score of  >12.5 kPa as per national protocols 
(at time of testing).   
The data were analysed using SPSS v24. Descriptive statistics (frequencies, percentages, 
median and interquartile range (IQR)) were used to summarise subjects’ characteristics. In 
analysing Phase Three data we used unadjusted negative binomial regression (NBR) models 
to examine the factors associated with the number of specialist care visits. The following 
explanatory variables were considered; age, gender, alcohol and drug use, key worker 
involvement and accommodation status. This model has been shown to have better fit than 
Poisson regression models by accounting for statistical overdispersion and excess zeros 
(individuals with no specialist care visits) and yields a more conservative result. The 
parameter estimates from the NBR models were converted to incidence rate ratios (IRRs) by 
exponentiating the regression coefficients, and 95% confidence intervals were estimated. 
Incidence rate ratio above 1.0 implies higher number of specialist care visit and IRR below 
1.0 implies lower number of specialist care visits. 
 
Results 
Phase One- Screening and Survey 
A total of 597 subjects were offered HCV screening and recruited into the study, their median 
(IQR) age was 36 (29-43) years and 438 (73%) were male. Self-reported information 
regarding IV drug use was complete on 157 subjects, with 54% reporting current IV drug use. 
Characteristics of the sample recruited into the HepCheck Dublin study are presented in 
Table 1.  
{Insert Table 1 ‘Characteristics of sample recruited into the HepCheck Dublin study’ here} 
Out of 597 recruited subjects, only 353 provided information on previous HCV screening. Of 
the 353, 223 (63%) reported having been screened previously for HCV of whom 100 (45%) 
indicated the results being positive, 78 (35%) negative and 45 (20%) were unsure (Table 2). 
Almost half of those with reported previous HCV screening indicated the screening having 
been conducted more than two years ago. 
During Phase 1, we conducted HCV Ab tests in 538/597 subjects (59 opted out). Of those 
who received an HCV Ab test, 199 (37%) tested positive, 308 (57%) negative and 31 (6%) 
were recorded as no result. Of the 199 testing positive, 56% (112) were “new” positives, in 
that they did not report having had a previous positive HCV Ab test, indicating an overall 
undiagnosed HCV prevalence of 19% (112/597). The remainder of those testing positive 
were known positives (Table 3). 
{Insert Table 2 ‘Previous HCV Screening/follow-up’ here} 
{Insert Table 3 ‘HepCheck Screening Intervention’ here} 
Phase Two- In-Depth Questionnaire  
Forty eight subjects who reported previously testing positive for HCV in Phase 1 were 
willing to participate in Phase 2 and complete a researcher administered questionnaire. The 
majority were male (69%), and 78% were currently living in a hostel. The remaining were 
‘sofa surfing’, sleeping rough or staying with friends. 85% were homeless for longer than one 
year. The average time period of homelessness was 6.2 years, with a range of 2 months to 20 
years. The most common reasons for homelessness were co-morbidities such as alcohol 
and/or drugs, and for some, this was combined with family/relationship problems and mental 
health problems. Forty-two percent reported seeing a GP once per week for unspecified 
reasons. In order to assess morbidity, respondents were read a list of physical and mental 
health problems and asked ‘Have you ever been told by a doctor that you have one of the 
following?’ Table 4 illustrates their health status. Depression and anxiety, dental problems 
and respiratory conditions were common reported health problems (Figure 1). 69% reported 
use of drugs in the past 30 days, with 45% ever sharing needles and 73% currently attending 
a drug treatment centre.  
{Insert Table 4 ‘Health Status’ here} 
{Insert Figure 1 here} 
When asked about the status of their HCV infection, 77% disclosed that they were unaware 
of the current status of their infection, 9% reported that they had cleared the infection / 
attained sustained viral response (SVR), and 6% had ‘active’ infection. Regarding 
engagement with follow-up, 63% (n=30) had been previously referred to specialist care, and 
among these 60% (n=18) had attended at least one appointment. 50% (n=9) of those who had 
attended specialist care previously had stopped attending (Table 5). When asked about their 
HCV healthcare pathway, unstable accommodation was reported to be the most common 
barrier to attending specialist appointments and accessing treatment.  The most common 
other reasons for non-attendance were active drug use, being in prison, fear of side effects of 
treatment and forgetfulness.  
{Insert Table 5 ‘Historic HCV Care Processes’ here} 
Phase Three- Referral and Outcome Tracking 
Following a positive HCV Ab test, 46 subjects were referred to specialist care, of which 21 
attended at least two appointments. Seven subjects received a Fibroscan or ultrasound. At 
time of writing, two subjects had completed treatment. See Figure 2.  
{Insert ‘Figure 2’ here} 
Table 6 below shows factors associated with specialist care visits. In the unadjusted NBRs for 
Phase 3, no associations were observed between the number of specialist care visits and the 
examined factors: age, gender, drug or alcohol use, stable accommodation status and key 
worker involvement.  
{Insert Table 6 ‘Unadjusted negative binomial regression for factors associated with 
specialist care visits’ here} 
Discussion 
This is the first study in Ireland to specifically target and characterise homeless individuals 
and their prevalence of HCV and experiences of the HCV care pathway. The study presents a 
unique Irish profile of HCV burden among homeless patients accessing primary care services 
in Dublin, Ireland, and illustrates the complexities around provision of an intensified 
screening programme for HCV for homeless populations. The strengths of the study include 
the selection of a particularly hard to reach group of homeless individuals in Dublin, who are 
a HCV risk population who need to be studied and intervened with in order to better 
understand how to improve their experiences of HCV assessment and treatment. 
The study highlights the complexities around provision of HCV cascade of care to homeless 
individuals living in Dublin. Not having stable accommodation is a major barrier to screening 
and treatment retention. Studies elsewhere in Europe have indicated how structural factors 
impede HCV screening and treatment access, with key barriers centring on social stigma, 
housing, criminalisation, healthcare systems, and gender (28).   
As highlighted previously, hospital-based appointments are the only model of care available 
in Ireland. This study demonstrates that standard referral methods are inadequate in engaging 
this population. The current referral process exacerbates barriers to treatment engagement. 
Due to the transient nature of the cohort there are difficulties in contacting and sending 
reminders for appointments. To compound this further, not all participants had access to a 
keyworker to facilitate the referral process. 
The opportunistic community-based screening uncovered concerning numbers of HCV Ab 
positive individuals in those accessing SafetyNet services, with 37% of individuals testing 
positive for HCV antibodies. Of note is that over half were ‘new positives’ and just under 
half were ‘known positives’, which underscores the need to enhance patient engagement with 
the HCV cascade of care, and to completion. Studies in Dublin have pointed to the issues 
around other disease morbidities in this population where symptoms of alcohol or drug 
withdrawals may mask HCV symptoms (24). This highlights that symptom-based testing for 
HCV is futile, further emphasising the necessity for broad risk-based and network-based 
strategies in effectively identifying cases (5,29).                                                                                                                                                                      
The study supports Crowley et al. (2017) by emphasising the need to consistently target 
homeless individuals, particularly those who are actively using or have a history of injecting 
drug use, for HCV screening and treatment. Marginalised injecting drug users, especially 
those who are without stable accommodation are a hard to reach group and are less likely to 
access health care due to fear of discrimination, stigma, low health literacy, and health 
professional misunderstanding of their needs (20,30–32). Homeless patient characteristics in 
our study are equally complex in terms of physical and mental health problems such as 
continued drug/alcohol use, being on drug treatment, and experiencing forgetfulness, 
depression and anxiety, respiratory and dental conditions, all of which confound the HCV 
treatment care pathway. Reasons for non-attendance of HCV care such as active drug use, 
being incarcerated, fear of HCV treatment side effects and forgetfulness are similar to those 
reported by Crowley et al. (2017) in their study of Irish patient characteristics and barriers to 
Hepatitis C treatment in patients on opioid substitution treatment (OST) attending a 
community-based clinic where Fibroscans were performed. 
Scaling up of HCV prevention, screening and treatment to address HCV transmission among 
the homeless, particularly those injecting drugs within existing community-based 
infrastructures and primary care are warranted (20,31–33). Of note is that among Phase 2 
participants, 42% saw a GP once a week. This suggests a potential for high engagement 
within community-based primary care settings. A recent study by Barocas et al. (2017) 
describes excellent responses to community-based HCV treatment within a primary care 
program in a cohort of homeless and marginally housed adults, demonstrating that despite 
barriers and competing priorities, outcomes similar to those of clinical trials and other cohorts 
are possible for this traditionally difficult to treat group (34). Similarly, Grebely et al. (2017) 
describes an effective implementation of point-of-care HCV RNA testing in people attending 
drug health and homelessness services in Australia, showing potential for improved 
screening, linkage to care and treatment retention (35). 
We recognise that whilst community-based screening intervention can determine the 
prevalence of HCV in homeless populations, referrals to / attendance at secondary care 
remains a challenge for this cohort. Psychosocial factors are at the core of why patients do 
not attend secondary care for HCV management and in this study, the interplay between 
addiction, mental health and homelessness were especially problematic. With this in mind, 
community-based health services such as Safetynet are ideally placed to support HCV 
screening and facilitate vulnerable individuals in accessing the treatment and care pathway. 
This study demonstrates that the current hospital-based model of care is inadequate in 
addressing the specific needs of this population, reflected in only 2 of the 199 individuals 
testing positive accessing treatment and cure. This emphasises the need for a community-
based treatment approach.  
Limitations 
A notable limitation of this study is missing data. Participating services were highly 
burdened, with a large volume of people accessing primary care and although there was high 
uptake of screening, a high number of questionnaires were incomplete as immediate health 
concerns took precedence in the limited consultation time. This meant that we were not as 
fully able to explore patient characteristics and barriers to access. 
It is important to note that the HepCheck study was carried out during a homelessness crisis 
in Dublin. Sourcing accommodation on a nightly basis was an unfortunate reality for many of 
the participants in this study.  
Conclusion 
The homeless population remain a high risk and high prevalence population for HCV   
infection (8–10). Health literacy, screening uptake and treatment engagement are challenging 
given the complexities of this patient cohort. Findings from this study represent a first step in 
Ireland to understanding the needs of homeless individuals and are intended to inform 
HepCare Europe in their development of a community-based model of care in order to 
engage with homeless individuals who are infected with or affected by HCV. 
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 Figure legend: 
Figure 1 title: ‘Distribution of morbidities in Phase 2 subjects who reported previous positive 
HCV test in Phase 1’ 
Figure 2 title: ‘Screening flowchart’ 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
597 consented for 
inclusion and offered 
screening 
59 declined 
screening 
538 screened 
308 Ab- 
199 Ab+ 
Of which: 
112 new positives 
87 known positives 
31 no result 
46 referrals 
21 attendees of at least 
two appointments 
7 received Fibroscan 
2 completed treatment 
 Table 1: Characteristics of the sample recruited into the HepCheck Dublin study 
 N=597 
Age - years (median (IQR)) 36 (29-43) 
Gender n (%) 
   Male 438 (73%) 
   Female 159 (27%) 
*Ethnicity (n=286) 
   Irish 281 (98%) 
   Other European 5 (2%) 
*Temporary emergency accommodation1 (n=247) 
   Yes 177 (72%) 
   No 70 (28%) 
*Key worker involvement (n=194)  
   Yes 143 (74%) 
   No 51 (26%) 
*Injection drug use (n=157) 
   Current2 84 (54%) 
   Past 68 (43%) 
   Never 5 (3%) 
*Alcohol use3 (n=193) 
   Yes 72 (37%) 
   No 121 (63%) 
Note ethnicity missing 311 responses, temporary emergency accommodation missing 350 responses, key worker 
missing 403 responses, injecting drug use missing 440 responses and alcohol use missing 404 responses 
*Proportions based on complete cases with response available on the characteristic 
IQR: interquartile range  
1
 Secured for 6 months 
2 In past month 
3 Self-reported problematic alcohol use 
 
 
 
 
 Table 2: Proportion of subjects with previous HCV screening and details of previous 
screening 
 n (%) 
Number who responded 353/597 (59%) 
Previously screened (n=353) 
   Yes 223 (63%) 
  No 130 (37%) 
If previously screened, when? (n=223) 
  6 months 47 (21%) 
  1 year 52 (23%) 
  2+ years 108 (48%) 
  Unknown 16 (7%) 
Results of those previously screened (n=223) 
  Positive 100 (45%) 
  Negative 78 (35%) 
  Unsure 45 (20%) 
Previously offered treatment 34 (34%) 
 
 
 Table 3: Phase 1 HepCheck Screening Intervention results 
 n (%) 
Received HCV Ab test (n=597) 
   Yes 538 (90%) 
   No 59 (10%) 
HCV Ab test results (n=538) 
   Positive 199 (37%) 
   Negative 308 (57%) 
   No result 31 (6%) 
Classification of HCV Ab positives (n=199) 
   New positives 112 (56%) 
   Known positives 87 (44%) 
HCV Ag testing on Ab positives (n=112) 
   Yes 13 (12%) 
   No 99 (88%) 
HCV Ag results (n=13) 
   Positive 12 (92%) 
   Negative 0 (0%) 
   Unknown 1 (8%) 
HCV: Hepatitis C Virus, Ab: antibody, Ag: antigen 
 
 
 Table 4: Health Status in Phase 2 subjects who reported previous positive HCV test in 
Phase 1 
 n=48 
Self-rated health  
   Good to excellent 14 (29%) 
   Fair to poor 33 (69%) 
   Health worse than one year ago 21 (44%) 
Service usage  
   No medical card 18 (38%) 
   Not registered with a GP 14 (29%) 
   Attended ED in past six months 31 (65%) 
Medications  
   On prescription medication 37 (77%) 
Drug use and addiction  
Illicit drug use in the past 30 days  
   Heroin  34 (71%) 
   Benzodiazepines 23 (48%) 
   Crack cocaine 11 (23%) 
   Other 10 (21%) 
Age of first IV drug use (N=44)  
   <12 years 1 (2%) 
   12-14 years 6 (14%) 
   14-16 years 7 (16%) 
   16-18 years 5 (11%) 
   18-21 years 8 (18%) 
   21 and over 17 (39%) 
Ever shared needles 20 (42%) 
Currently attending drug treatment centre 32 (67%) 
ED: Emergency Department, IV: Intravenous, GP: General Practitioner  
 
 Table 5: Historic HCV care processes in Phase 2 subjects who reported previous positive 
HCV test in Phase 1 
 n=48 
Tested for Hepatitis C  
   Positive diagnosis 48 (100%) 
Status of infection  
   Cleared/SVR 4 (8%) 
   Chronic 6 (13%) 
   Unknown 38 (79%) 
Further testing  
   Ultrasound 18 (38%) 
   Liver biopsy 7 (15%) 
   Fibroscan 2 (4%) 
Referred to specialist care 30 (63%) 
Attended specialist care 18 (38%) 
   Stopped attending 9 (19%) 
   Offered treatment 7 (15%) 
Not treated, but would like to be treated now 34 (71%) 
SVR: Sustained virologic response 
 
 
 Table 6: Unadjusted negative binomial regression for factors associated with specialist care 
attendance 
Characteristics IRR 95% CI P-Value 
Age (per 5-year increment) 0.92 0.78-1.10 0.37 
Gender 
Female Referent   
Male 1.45 0.72-2.89 0.28 
Drug/alcohol use 
Yes 0.82 0.45-1.49 0.51 
No Referent   
Accommodation for six months 
Yes 1.69 0.64-4.47 0.29 
No Referent   
Key Worker    
Yes 1.48 0.57-3.82 0.41 
No Referent   
 
IRR: incidence rate ratio; CI: confidence interval 
 
 
 
